

Abteilung "Neurologie"

Journalbeiträge

1. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Janssens U, Klima U, Klippe HJ, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2004) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. *Intensivmed*, 41 (8): 618-26.
2. Alfonso J, Aguero F, Sanchez DO, Flugge G, Fuchs E, Frasch AC, Pollevick GD (2004) Gene expression analysis in the hippocampal formation of tree shrews chronically treated with cortisol. *J NEUROSCI RES*, 78(5): 702-10.
3. Alfonso J, Pollevick GD, Van Der Hart MG, Flüggé G, Fuchs E, Frasch AC (2004) Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. *EUROPEAN JOURNAL OF NEUROSCIENCE*, 19(3): 659-66.
4. Baier PC, Schindehütte J, Thinyane K, Flüggé G, Fuchs E, Mansouri A, Paulus W, Gruss P, Trenkwaldler C (2004) Behavioral changes in unilaterally 6-hydroxy-dopamine lesioned rats after transplantation of differentiated mouse embryonic stem cells without morphological integration. *STEM CELLS*, 22(3): 396-404.
5. Bailey DM, Kleger GR, Holzgraefe M, Ballmer PE, Bartsch P (2004) Pathophysiological significance of peroxidative stress, neuronal damage and membrane permeability in acute mountain sickness. *J APPL PHYSIOL*, 96(4): 1459-63.
6. Bartels E, Bittermann HJ (2004) Transcranial contrast imaging of cerebral perfusion in stroke patients following decompressive craniectomy. *Ultraschall in der Medizin*, 25(3): 206-13.
7. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rütther E, Kornhuber J, Wiltfang J (2004) Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. *ELECTROPHORESIS*, 25(17): 2912-8.
8. Bitsch A, Bahner D, Wachter C, Elitok E, Bogumil T, Dressel A, Polak T, Tumani H, Weber F, Poser S, Kitze B (2004) Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. *ACTA NEUROL SCAND*, 110(6): 386-92.
9. Bitsch A, Dressel A, Meier K, Bogumil T, Deisenhammer F, Tumani H, Kitze B, Poser S, Weber F (2004) Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. *J NEUROL*, 251(12): 1498-501.
10. Böttcher T, Ren H, Goigny M, Gerber J, Lykkesfeldt J, Kuhnt U, Lotz M, Bunkowski S, Werner C, Schau I, Spreer A, Christen S, Nau R (2004) Clindamycin is neuroprotective in experimental *Streptococcus pneumoniae* meningitis compared with ceftriaxone. *J NEUROCHEM*, 91(6): 1450-60.
11. Cepek L, Bahn E, Prange H (2004) Klinik und Therapie der septisch-embolischen Herdenzephalitis. *Psychoneuro*, 30 (12): 667-671.
12. Dietz GP, Bähr M (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. *MOL CELL NEUROSCI*, 27(2): 85-131.
13. Dorta-Contreras AJ, Reiber H (2004) [Molecular diffusion/cerebrospinal fluid flow theory]. *REV NEUROLOGIA*, 39(6): 564-9.
14. Dorta-Contreras AJ, Noris-García E, Reiber H (2004) [Reibergram for immunoglobulin E intrathecal synthesis evaluation]. *REV NEUROLOGIA*, 39(8): 794-5.
15. Ehrenreich H (2004) A boost for translational neuroscience. *SCIENCE*, 305(5681): 184-5.
16. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, Sirén AL (2004) Erythropoietin: novel approaches to neuroprotection in human brain disease. *METAB BRAIN DIS*, 19(3-4): 195-206.
17. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, Woldt H, Falkai P, Knerlich F, Jacob S, von Ahsen N, Maier W, Bruck W, Ruther E, Cerami A, Becker W, Siren AL (2004) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. *MOL PSYCHIATR*, 9(1): 42-54.
18. Ehrenreich H, Timmer W, Sirén AL (2004) A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. *TRANSFUS APHER SCI*, 31(1): 39-44.
19. Fassbender K, Walter S, Kühl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K (2004) The LPS receptor (CD14) links innate immunity with Alzheimer's disease. *FASEB J*, 18(1): 203-5.
20. Fuchs E, Czeh B, Flugge G (2004) Examining novel concepts of the pathophysiology of depression in the chronic psychosocial stress paradigm in tree shrews. *BEHAV PHARMACOL*, 15(5-6): 315-25.
21. Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ (2004) Alterations of neuroplasticity in depression: the hippocampus and beyond. *EUR NEUROPSYCHOPHARM*, 14 Suppl 5: S481-90.
22. García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA (2004) Mechanism of block of hEag1 K⁺ channels by imipramine and astemizole. *J GEN PHYSIOL*, 124(4): 301-17.

Abteilung "Neurologie"

23. George A, Schneider-Gold C, Zier S, Reiners K, Sommer C (2004) Musculoskeletal pain in patients with myotonic dystrophy type 2. *ARCH NEUROL-CHICAGO*, 61(12): 1938-42.
24. Gerber J, Bottcher T, Hahn M, Siemer A, Bunkowski S, Nau R (2004) Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. *NEUROBIOL DIS*, 16(1): 133-8.
25. Gerber J, Schmidt H, Nau R (2004) Akute bakterielle Meningitis. *Psychoneuro*, 30 (12): 672-6.
26. Grandis M, Leandri M, Vigo T, Cilli M, Sereda MW, Gherardi G, Benedetti L, Mancardi G, Abbruzzese M, Nave KA, Nobbio L, Schenone A (2004) Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. *EXP NEUROL*, 190(1): 213-23.
27. Grasbon-Frodl E, Schmalzbauer R, Weber P, Krebs B, Windl O, Zerr I, Kretzschmar HA (2004) A novel three extra-repeat insertion in the prion protein gene (PRNP) in a patient with Creutzfeldt-Jakob disease. *NEUROGENETICS*, 5(4): 249-50.
28. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K (2004) Value of CSF beta-amyloid(1-42) and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. *MOL PSYCHIATR*, 9(7): 705-10.
29. Hermening S, Kügler S, Bähr M, Isenmann S (2004) Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron sequence. *J VIROL METHODS*, 122(1): 73-7.
30. Herrlinger U, Aulwurm S, Strik H, Weit S, Naumann U, Weller M (2004) MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model. *J NEURO-ONCOL*, 66(1-2): 147-54.
31. Hobom M, Storch MK, Weissert R, Maier K, Radhakrishnan A, Kramer B, Bähr M, Diem R (2004) Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. *BRAIN PATHOL*, 14(2): 148-57.
32. Iliev AI, Stringaris AK, Nau R, Neumann H (2004) Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). *FASEB J*, 18(2): 412-4. Epub 2003 Dec 19.
33. Keuker JI, de Biurrun G, Luiten PG, Fuchs E (2004) Preservation of hippocampal neuron numbers and hippocampal subfield volumes in behaviorally characterized aged tree shrews. *J COMP NEUROL*, 468(4): 509-17.
34. Kilic E, Weishaupt JH, Kilic U, Rohde G, Yulug B, Peters K, Hermann DM, Bähr M (2004) The superoxide dismutase1 (SOD1) G93A mutation does not promote neuronal injury after focal brain ischemia and optic nerve transection in mice. *NEUROSCIENCE*, 128(2): 359-64.
35. Kilic U, Kilic E, Lingor P, Yulug B, Bähr M (2004) Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. *ACTA NEUROPATHOL*, 108(1): 65-8.
36. Kilic Ü, Kilic E, Dietz G, Bähr M (2004) The TAT protein transduction domain enhances the neuroprotective effect of GDNF after optic nerve transection. *Neurodegenerative Dis*, 27 (2): 44-9.
37. Knabe W, Knerlich F, Washausen S, Kietzmann T, Sirén AL, Brunnett G, Kuhn HJ, Ehrenreich H (2004) Expression patterns of erythropoietin and its receptor in the developing midbrain. *ANAT EMBRYOL*, 207(6): 503-12.
38. Koeberle PD, Bähr M (2004) Growth and guidance cues for regenerating axons: where have they gone? *J NEUROBIOL*, 59(1): 162-80.
39. Koeberle PD, Gaudie J, Ball AK (2004) Effects of adenoviral-mediated gene transfer of interleukin-10, interleukin-4, and transforming growth factor-beta on the survival of axotomized retinal ganglion cells. *NEUROSCIENCE*, 125(4): 903-20.
40. Kole MH, Costoli T, Koolhaas JM, Fuchs E (2004) Bidirectional shift in the cornu ammonis 3 pyramidal dendritic organization following brief stress. *NEUROSCIENCE*, 125(2): 337-47.
41. Kole MH, Czeh B, Fuchs E (2004) Homeostatic maintenance in excitability of tree shrew hippocampal CA3 pyramidal neurons after chronic stress. *HIPPOCAMPUS*, 14(6): 742-51.
42. Kretz A, Kügler S, Happold C, Bähr M, Isenmann S (2004) Excess Bcl-XL increases the intrinsic growth potential of adult CNS neurons in vitro. *MOL CELL NEUROSCI*, 26(1): 63-74.
43. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J (2004) Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. *J MOL NEUROSCI*, 23(1-2): 115-22.
44. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J (2004) Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. *BIOL PSYCHIATR*, 55(5): 524-30.
45. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. *NEUROBIOL AGING*, 25(3): 273-81.

Abteilung "Neurologie"

46. Lingor P, Michel U, Schöll U, Bähr M, Kügler S (2004) Transfection of "naked" siRNA results in endosomal uptake and metabolic impairment in cultured neurons. *BIOCHEM BIOPH RES CO*, 315(4): 1126-33.
47. Lingor P, Michel U, Bahr M (2004) The long process of short interfering RNA - RNAi in neuronal cells. *Neurodegenerative Dis*, 1: 3-8.
48. Linker RA, Gold R (2004) MBP-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. *J IMMUNOL*, 173(5): 2896.
49. Lucassen PJ, Fuchs E, Czeh B (2004) Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. *BIOL PSYCHIAT*, 55(8): 789-96.
50. Lütjohann D, Stroick M, Bertsch T, Kühl S, Lindenthal B, Thelen K, Andersson U, Björkhem I, Bergmann KV, Fassbender K (2004) High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. *STEROIDS*, 69(6): 431-8.
51. Maier K, Rau CR, Storch MK, Sättler MB, Demmer I, Weissert R, Taheri N, Kuhnert AV, Bähr M, Diem R (2004) Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. *BRAIN PATHOL*, 14(4): 378-87.
52. Meissner B, Köhler K, Körtner K, Bartl M, Jastrow U, Mollenhauer B, Schröter A, Finkenstaedt M, Windl O, Poser S, Kretzschmar HA, Zerr I (2004) Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. *NEUROLOGY*, 63(3): 450-6.
53. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA (2004) Axonal neuregulin-1 regulates myelin sheath thickness. *SCIENCE*, 304(5671): 700-3.
54. Nau R, Gerber J, Bunkowski S, Brück W (2004) Axonal injury, a neglected cause of CNS damage in bacterial meningitis. *NEUROLOGY*, 62(3): 509-11.
55. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kretzschmar HA, Poser S, Prange H (2004) Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. *NEUROLOGY*, 62(5): 714-8.
56. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, Lewis V, Sutcliffe T, Guilivi A, Delasnerie-Laupretre N, Brandel JP, Alperovitch A, Zerr I, Poser S, Kretzschmar HA, Ladogana A, Rietvald I, Mitrova E, Martinez-Martin P, de Pedro-Cuesta J, Glatzel M, Aguzzi A, Cooper S, Mackenzie J, van Duijn CM, Will RG (2004) Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. *BRAIN*, 127(Pt 10): 2348-59.
57. Pohl D, Rostasy K, Reiber H, Hanefeld F (2004) CSF characteristics in early-onset multiple sclerosis. *NEUROLOGY*, 63(10): 1966-7.
58. Quentin CD, Reiber H (2004) Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. *AM J OPHTHALMOL*, 138(1): 46-54.
59. Rüchel R, Elsner C, Spreer A (2004) A probable cause of paradoxical thrombosis in zygomycosis. *MYCOSES*, 47(5-6): 203-7.
60. Sättler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, Diem R (2004) Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. *CELL DEATH DIFFER*, 11 Suppl 2: S181-92.
61. Schmidt H, Otto M, Niedmann P, Cepek L, Schroter A, Kretzschmar HA, Poser S (2004) CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias. *DEMENT GERIATR COGN*, 17(3): 204-6. Epub 2004 Jan 20.
62. Schmidt H, Nau R (2004) Therapie der bakteriellen Meningitis. *AKTUEL NEUROL*, 31: 231-40.
63. Schneider-Gold C (2004) Myotonic dystrophy: present management, future therapy (2004) P.S. Harper, B.G.M. van Engelen, B. Eymard, D.E. Wilcox (Editors): 1st edition, Oxford University Press, Oxford, ISBN 0198-52782-9, hardcover, pound 55. *HUM GENET*, -: -.
64. Schneider-Gold C, Hartung HP (2004) Myasthenia gravis: pathology, diagnosis and treatment. *FORTSCHR NEUROL PSYC*, 72(1): 45-56; quiz 56-7.
65. Schneider-Gold C, Beer M, Köstler H, Buchner S, Sandstede J, Hahn D, Toyka KV (2004) Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative ³¹P-MRS and MRI study. *MUSCLE NERVE*, 30(5): 636-44.
66. Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Dürre J, Bültmann B, Kress W, Day JW, Ranum LP (2004) Sudden cardiac death in myotonic dystrophy type 2. *NEUROLOGY*, 63(12): 2402-4.
67. Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, Pongratz DE, Toyka KV, Lochmüller H, Ricker K (2004) Muscle pathology in 57 patients with myotonic dystrophy type 2. *MUSCLE NERVE*, 29(2): 275-81.
68. Schuchhardt V, Prange H (2004) Tuberkulöse ZNS-Erkrankungen. *Psychoneuro*, 30 (12): 651-4.
69. Spreer A, Lis A, Gerber J, Reinert RR, Eiffert H, Nau R (2004) Differences in clinical manifestation of *Streptococcus pneumoniae* infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids. *J CLIN MICROBIOL*, 42(7): 3342-5.

Abteilung "Neurologie"

70. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. *NEUROSCI LETT*, 370(1): 36-9.
71. Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA (2004) Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. *ANN NEUROL*, 56(5): 702-8.
72. Strik HM, Spreer A, Nagel H, Jacob S, Jung W, Kitze B, Bähr M (2004) Clinical response following adjuvant Temozolomide in a patient with primary cerebral lymphoma. *ANTICANCER RES*, 24(6): 4121-5.
73. Strik HM, Stoll M, Meyermann R (2004) Immune cell infiltration of intrinsic and metastatic intracranial tumours. *ANTICANCER RES*, 24(1): 37-42.
74. Weise J, Crome O, Sandau R, Schulz-Schaeffer W, Bähr M, Zerr I (2004) Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. *NEUROSCI LETT*, 372(1-2): 146-50.
75. Weise J, Kuschke S, Bähr M (2004) Gender-specific risk of perioperative complications in carotid endarterectomy patients with contralateral carotid artery stenosis or occlusion. *J NEUROL*, 251(7): 838-44.
76. Weishaupt JH, Rohde G, Pölkling E, Siren AL, Ehrenreich H, Bähr M (2004) Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. *INVEST OPHTH VIS SCI*, 45(5): 1514-22.
77. Wellmer A, von Mering M, Spreer A, Diem R, Eiffert H, Noeske C, Bunkowski S, Gold R, Nau R (2004) Experimental pneumococcal meningitis: impaired clearance of bacteria from the blood due to increased apoptosis in the spleen in Bcl-2-deficient mice. *INFECT IMMUN*, 72(6): 3113-9.
78. Yulug B, Kilic U, Kilic E, Bähr M (2004) Rifampicin attenuates brain damage in focal ischemia. *BRAIN RES*, 996(1): 76-80.
79. Zerr I, Poser S (2004) Epidemiology and risk factors of transmissible spongiform encephalopathies in man. *Contrib Microbiol*, 11: 98-116.
80. Zerr I, Bodemer M, Kaboth U, Kretzschmar H, Oellerich M, Armstrong VW (2004) Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease. *NEUROSCI LETT*, 371(2-3): 163-6.

Buchbeiträge

1. Adams HA, Bauer M, Baumann G, Cascorbi I, Geiger S, Jansens U, Klippe HJ, Knoefel WT, Müller-Werdan U, Prange H, Schareck W, Schürholz T, Standl T, Teske W, Werner G, Windolf J, Zander R (2004) Hypovolämischer Schock (8. Ergänzungslieferung). In: Eckart J, Forst H, Burchardi H (Hg.) *Intensivmedizin. Kompendium und Repetitorium zur interdisziplinären Weiter- und Fortbildung*. Ecomed Verlag, Landsberg/Lech, 1-20.
2. Bitsch A, Prange H (2004) Lumbalpunktion, Subokzipitalpunktion, lumbale Drainage. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 41-4.
3. Ehrenreich H, Siren AL (2004) Erythropoietin: A beneficial Approach to Neuroprotection in Stroke. In: Buchan A, Ito M, Colbourne F, Kuroiwa T, Klatzo I (Hg.) *Maturation Phenomenon in Cerebral Ischemia V*. Springer Verlag, Berlin, 63-4.
4. Fuchs E (2004) Animal models of depression. In: Olie JP, Costa da Silva JA, Macher JP (Hg.) *Neuroplasticity: a new approach to the pathophysiology of depression*. Science Press, London, 39-50.
5. Fuchs E, Flügge G (2004) Animal models of anxiety disorders. In: Charney DS, Nestler EJ (Hg.) *The neurobiology of mental illness*. Oxford University Press, Oxford, 546-57.
6. Prange H (2004) Monitoring des erhöhten intrakraniellen Drucks (ICP). In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 15-20.
7. Prange H (2004) Intrakranielle Blutungen. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 86-104.
8. Prange H (2004) Hirninfarkt. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 67-80.
9. Prange H (2004) Infektionserkrankungen des Nervensystems. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 105-34.
10. Prange H (2004) Akinetische Krise und verwandte Krankheitsbilder. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 186-8.
11. Prange H (2004) Akute Schwächesyndrome bei Intensivpatienten. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 193-6.
12. Prange H (2004) Intoxikationen. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 218-25.
13. Prange H (2004) Prinzipien der Antibiotikatherapie bei Intensivpatienten. In: Prange H, Bitsch A (Hg.) *Neurologische Intensivmedizin*. Thieme Verlag, Stuttgart, 282-91.

Abteilung "Neurologie"

14. Prange H (2004) Enterale und parenterale Ernährung. In: Prange H, Bitsch A (Hg.) Neurologische Intensivmedizin. Thieme Verlag, Stuttgart, 272-81.
15. Prange H (2004) Therapie des erhöhten intrakraniellen Druckes. In: Prange H, Bitsch A (Hg.) Neurologische Intensivmedizin. Thieme Verlag, Stuttgart, 255-64.
16. Prange H (2004) Hypoxische Hirnschädigung. In: Prange H, Bitsch A (Hg.) Neurologische Intensivmedizin. Thieme Verlag, Stuttgart, 214-7.
17. Prange H (2004) Stiff-Man-Syndrom (SMS). In: Prange H, Bitsch A (Hg.) Neurologische Intensivmedizin. Thieme Verlag, Stuttgart, 189-90.
18. Prange H (2004) Erkrankungen mit gestörtem Liquorabfluss. In: Prange H, Bitsch A (Hg.) Neurologische Intensivmedizin. Thieme Verlag, Stuttgart, 178-83.
19. Weise J, Bähr M (2004) Molekulare Veränderungen beim ischämischen Schlaganfall. In: Ganten D, Ruckpaul K (Hg.) Molekularmedizinische Grundlagen altersspezifischer Erkrankungen. Springer Verlag, Berlin/Heidelberg, 228-55.

Monographien

1. Kitzte B (2004) Die Spezifität der systemischen und intrathekalen Immunantwort bei der Infektion mit dem humanen T-lymphotropen Virus (HTLV-1). Shaker Verlag, Aachen.